ReviewNature metabolism2024
Metabolic heterogeneity in cancer.
Review in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis.British journal of cancer · 2026Pooled it
- The metabolic syndrome-cancer axis: global research trends and clinical landscapes.Frontiers in endocrinology · 2026Pooled it
- Metabolomics and metabolites in cancer diagnosis and treatment.Molecular biomedicine · 2025Pooled it
- Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.Blood advances · 2026Trial
- Glucose and Oxygen Availability Shape Growth and Architecture of Tumor Spheroids in a Microfluidic 3D Model.Annals of biomedical engineering · 2026Article
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Macrophage-supported metabolic adaptation drives tumor survival under nutrient stress.Science advances · 2026Article
- Review
- Lysine pyruvylation: decoding the molecular language of pyruvate signaling.EMBO molecular medicine · 2026Article
- ALDH1B1 promotes mitochondrial γ-butyrobetaine biosynthesis and fatty acid oxidation in colorectal cancer.bioRxiv : the preprint server for biology · 2026Article
- Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- PGC1α-mediated upregulation of PHD2 represses HIF-signaling, limiting prostate cancer progression.Cell death and differentiation · 2026Article
- Malic enzyme 1 senses L-lactate to determine tumor heterogeneity.Signal transduction and targeted therapy · 2026Article
- Sphingolipid Remodeling in Colorectal Cancer Reveals a Continuum-like Metabolic Organization.Antioxidants (Basel, Switzerland) · 2026Article
- Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy.Acta pharmaceutica Sinica. B · 2026Article
- High-spatiotemporal resolution deuterium metabolic imaging enables in vivo phenotyping of intra- and intertumoral heterogeneity.Science advances · 2026Article
- A high-resolution circulating metabolic atlas of lung adenocarcinoma progression supports early and accurate diagnosis.Cell reports. Medicine · 2026Article
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer cells rewire their metabolism to survive during cancer progression. In this context, tumour metabolic heterogeneity arises and develops in response to diverse environmental factors. This metabolic heterogeneity contributes to cancer aggressiveness and impacts therapeutic opportunities. In recent years, technical advances allowed direct characterisation of metabolic heterogeneity in tumours. In addition to the metabolic heterogeneity observed in primary tumours, metabolic heterogeneity temporally evolves along with tumour progression. In this Review, we summarize the mechanisms of environment-induced metabolic heterogeneity. In addition, we discuss how cancer metabolism and the key metabolites and enzymes temporally and functionally evolve during the metastatic cascade and treatment.
Indexed as
Identifiers
38267631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.